+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiovascular Drugs Market Research Reports

Coronary Occlusion - Epidemiology Forecast to 2032 - Product Thumbnail Image

Coronary Occlusion - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Renal vasculitis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Renal vasculitis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Sick sinus syndrome - Epidemiology Forecast - 2032 - Product Thumbnail Image

Sick sinus syndrome - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Supraventricular Tachycardia - Epidemiology Forecast - 2032 - Product Thumbnail Image

Supraventricular Tachycardia - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Venous Leg Ulcer - Epidemiology Forecast - 2032 - Product Thumbnail Image

Venous Leg Ulcer - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Venous Stenosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Venous Stenosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Ventral Hernia - Epidemiology Forecast - 2032 - Product Thumbnail Image

Ventral Hernia - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Ventricular Hypertrophy - Epidemiology Forecast - 2032 - Product Thumbnail Image

Ventricular Hypertrophy - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Abdominal Aneurysms - Epidemiology Forecast - 2032 - Product Thumbnail Image

Abdominal Aneurysms - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Early Cardiogenic Shock (CS) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Early Cardiogenic Shock (CS) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Pulmonary Hypertension - Epidemiology Forecast to 2032 - Product Thumbnail Image

Pulmonary Hypertension - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Giant-Cell Arteritis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Giant-Cell Arteritis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Recurrent Pericarditis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Recurrent Pericarditis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Arteriovenous Malformations - Epidemiology Forecast - 2032 - Product Thumbnail Image

Arteriovenous Malformations - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Cardiac Insufficiency - Epidemiology Forecast - 2032 - Product Thumbnail Image

Cardiac Insufficiency - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
ANCA Vasculitis - Epidemiology Forecast - 2032 - Product Thumbnail Image

ANCA Vasculitis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Aortic Stenosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Aortic Stenosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more